D-Fructose-1,6-bisphosphate sodium salt hydrate 是碳水化合物代谢的中间体,包括糖酵解和糖异生。在糖酵解过程中,它是由磷酸果糖激酶磷酸化果糖-6-磷酸产生的。由果糖-1,6-二磷酸酶-1介导的逆反应是糖异生的限速步骤之一。同样的反应也发生在植物的叶绿体中,D-Fructose-1,6-bisphosphate sodium salt hydrate 作为还原性戊糖磷酸循环的一部分。由于癌细胞采用糖酵解作为代谢能量产生的主要来源,这一途径已成为癌症化疗的主要靶点。
EP3 antagonist 3 (compound 2) is a highly effective and specific antagonist of the EP3 receptor. It displays significant oral bioavailability and exhibits a strong pKi value of 8.3. Furthermore, EP3 antagonist 3 possesses excellent pharmacokinetic characteristics, making it a suitable candidate for experimental investigations involving overactive bladder (OAB) research [1].
Phenanthridinium, 3-amino-8-(3-(3-(((aminoiminomethyl)hydrazono)methyl)phenyl)-1-triazenyl)-5-ethyl-6-phenyl-, chloride, monohydrochloride is a bioactive chemical.
GPVI antagonist 3 (Compound 2) is a potential antagonist that shows promising antiplatelet activity by selectively inhibiting the interaction between the Glycoprotein VI (GPVI) receptor and its ligands. It demonstrates potent inhibitory effects, with IC50 values of 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin, and 51.74 μM for thrombin. GPVI is a major collagen receptor on platelets, making it an ideal target for safe and effective antithrombotic treatment. Therefore, GPVI antagonist 3 holds potential as a novel antiplatelet agent [1].
TRPA1 Antagonist 3 is a compound with photoswitchable properties that acts as an agonist on the TRPA1 channel, providing the ability for optical control.